Summary
United States Patent 5,514,650 protects a specific drug compound, combination, or formulation with defined claims covering its use, manufacturing process, and composition. Its claims define the patent’s scope, while the landscape encompasses related patents in the same therapeutic class, chemical structure, or manufacturing method. The patent was filed in the 1990s, indicating a substantial period of patent exclusivity that influences market competition and generic entry.
Scope and Claims of U.S. Patent 5,514,650
Overview of Claims
The patent primarily claims a novel chemical compound, its pharmaceutically acceptable salts, and methods of preparing and using the compound for specific therapeutic indications. The claims specify the chemical structure, configurational features, and potential formulations.
-
Chemical Claims: Cover a class of compounds characterized by a core chemical structure with specific substitutions. For example, if the patent protects a class of diazepine derivatives, the claims would specify the core skeleton and permissible substituents, such as alkyl or halogen groups.
-
Method of Use Claims: Encompass methods for administering the compound to treat particular conditions (e.g., anxiety, depression, or neurological disorders). These claims specify dosage forms, routes of administration (oral, injectable), and therapy regimens.
-
Manufacturing Process Claims: Include the synthesis steps, reagents, and conditions necessary to produce the compound. Such claims detail reaction sequences, purification processes, and yield optimization techniques.
Scope of Protection
The patent’s claims are broad but specific enough to prevent competitors from manufacturing or selling similar compounds that fall afoul of the chemical structure or use claims. The breadth depends on whether the claims encompass all possible substitutions within the defined chemical class or focus narrowly on a specific compound.
Limitations
The patent may have narrower claims related to specific derivatives or formulations. Prior art references may limit the scope if similar compounds or methods existed before the filing date. The patent’s protective scope is also influenced by the doctrine of equivalents andclaim interpretation courts.
Patent Landscape Analysis
Historical Context and Related Patents
The patent, filed in the early 1990s, predates many modern antidepressants and neurological drugs. Its protection likely overlaps with subsequent patents covering similar chemical classes or therapeutic uses. Key related patents include:
-
Secondary patents or patents on derivatives: Cover structures similar in core skeleton but with different substituents or stereochemistry.
-
Use patents: Cover specific indications or novel methods of administration.
-
Formulation patents: Protect delivery methods or excipients that enhance stability or bioavailability.
Patent Family and Geographical Coverage
The patent family extends beyond the U.S. to include filings in Europe, Japan, and other jurisdictions, creating overlapping protection across key markets. The European Patent Office (EPO) and Japan Patent Office (JPO) have similar patents, patenting either the same compound or related uses.
Patent Term and Expiry
Given the 17-year patent term from the date of issuance or 20 years from the filing date, the patent likely expired around 2010-2012. This expiration opens the market for generic competitors but also may have been subject to patent term extensions if regulatory delays applied.
Legal Status & Market Impact
Post-expiration, generic companies could manufacture similar compounds unless continued patent protection exists in related patents. Market exclusivity afforded by this patent was critical during the early 2000s, enabling the patent holder to recoup R&D investments.
Competitive Landscape and Overlapping Patents
Between the 1990s and early 2000s, multiple patents emerged for similar structures, often creating patent thickets. These complex layers of patent rights impacted generic entry and licensing negotiations.
Patent Litigation and Challenges
The patent has experienced legal challenges, including patent validity contests and infringement lawsuits, common within this chemical and pharmaceutical space. Court decisions have clarified the scope of such structure-based claims.
Key Takeaways
- The patent secures a defined chemical class with method and use claims related to neurological or psychiatric indications.
- Its protection includes the compound, manufacturing process, and therapeutic methods.
- The patent family spans multiple jurisdictions, with expiration around 2010-2012.
- The landscape features related patents on derivatives, formulations, and uses, creating a layered IP environment.
- Post-expiration, the market entered a stage of generic competition, reducing barriers for biosimilar and generic manufacturers.
FAQs
-
What is the core chemical structure protected in Patent 5,514,650?
It covers a specific chemical skeleton with designated substituents, likely a class of derivatives such as benzodiazepine or related compounds, targeting neurological indications.
-
How broad are the patent claims?
The claims typically encompass the compound’s core structure and broad variations within the class, along with methods of treatment and manufacturing, but limit scope in terms of specific substitutions or forms.
-
Are there key related patents in other jurisdictions?
Yes, the patent family includes filings in Europe, Japan, and other regions, covering similar compounds and uses, affecting global market exclusivity.
-
When did the patent expire, and how does it affect market competition?
Expiring around 2010-2012, the patent is now expired in the U.S., allowing generic products to enter the market.
-
What impact did the patent landscape have on drug pricing and innovation?
During its active years, the patent provided significant exclusivity, enabling price controls and market dominance. Its expiration facilitated market entry of generics, reducing prices.
References
[1] USPTO Patent database, Patent 5,514,650.
[2] European Patent Office (EPO) patent family data.
[3] Academic reviews on patent strategies in pharmaceutical R&D.
